Stefan Alig

Also affiliated with University Hospital Heidelberg, Essen University Hospital, Stanford Medicine, West German Heart and Vascular Center Essen, Stanford University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling”.

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Nature(2023)10.1038/s41586-023-06903-x

N/A

2.5DataRank · unranked

111 citations

Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Y. Li, Cédric Rossi, Tim Flerlage +44 more

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Blood(2023)10.1182/blood.2022019254

N/A

1.4DataRank · unranked

39 citations

Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman +21 more

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Blood Advances(2022)10.1182/bloodadvances.2022008174

N/A

0.629DataRank · unranked

15 citations

Stefan Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu +16 more

Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8518

N/A

0.408DataRank · unranked

4 citations

Jacob J. Chabon, Brian J. Sworder, Lyron Co Ting Keh, Joanne Soo, Stefan Alig +10 more

Phased variants improve DLBCL minimal residual disease detection at the end of therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7565

N/A

0.348DataRank · unranked

3 citations

Jacob J. Chabon, Joanne Soo, Lyron Co Ting Keh, Stefan Alig, André Schultz +15 more

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

Nature Communications(2025)10.1038/s41467-025-62509-z

N/A

0.241DataRank · unranked

4 citations

Lei Feng, Jason R. Westin, Ranjit Nair, Luis Fayad, Maria Alma Rodriguez +14 more

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias

Research Square(2025)10.21203/rs.3.rs-7746241/v1

N/A

0.104DataRank · unranked

1 citations

Mark P. Hamilton, Nick Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio +32 more

Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas

Blood Advances(2023)10.1182/bloodadvances.2023011997

N/A

0DataRank · unranked

5 citations

Joseph G. Schroers‐Martin, Brian J. Sworder, Karan R. Kathuria, Stefan Alig, Matthew J. Frank +8 more

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Cancer Discovery(2020)10.1158/2159-8290.cd-19-0116

N/A

0DataRank · unranked

159 citations

Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain +24 more